EPZ004777 is >1,000-fold selective for DOT1L over other PMTs tested (CARM1, EHMT2, EZH1, EZH2, PRMT1, PRMT5, PRMT8, SETD7, WHSC1).
Probe Selectivity in Vitro:
Not available
In cell validation
Potency in cells:
IC50
700 nM
Potency assay (cells):
Dose-dependent decrease in the expression of HOXA9 and MEIS1 transcripts.
In MOLM-13, MLL-AF9, MV4-11, MLL-AF4, and Jurkat cells, EPZ004777 dose-dependently decreased DOT1L substrate methylation (H3K79) over 4-5 days as assessed by immunoblot.
Target engagement assay (cells):
Indirect, inhibition of substrate methylation in cells
Potency assay, off target (cells):
PRMT5 (H4R3), PRDMs ((H3K9) and SMYDs (H3K4) protein substrates were not impacted in cells.
Probe Selectivity in Cell:
Not available
In vivo validation
Organism:
Mice
Dose:
50 mg/mL continuous infusion
Route of delivery:
Subcutaneous
Organ (O):
MV4-11 xenograft
Target engagement assay:
Indirect, decrease in substrate methylation in the tumor.
Authors noted that EPZ004777 had a poor PK profile, which necessitated delivery by continuous infusion.